FRM
AVBP icon

Fox Run Management’s ArriVent BioPharma AVBP Stock Holding History

Fox Run Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Buy
+11,898
New +$351K 0.07% 549

Other funds holding AVBP

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $29.3B AUM 38.15% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return

Fox Run Management's AVBP Position: Q2 2026 in Review

Fox Run Management opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 11,898 shares worth $413K. The stake represents 0.07% of the portfolio and ranks #549 among its holdings.

24 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Fox Run Management held 11,898 shares of ArriVent BioPharma worth $413K as of Q2 2026.
  • ArriVent BioPharma was a new Fox Run Management position in Q2 2026.
  • ArriVent BioPharma made up 0.07% of Fox Run Management's portfolio in Q2 2026, its #549 holding.
  • 24 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.